Addyi, the libido-boosting pink pill for women, is expected to cost about $500 a month. But its maker, Sprout Pharmaceuticals, said this week that monthly co-pays will likely range from $30 to $75 for patients with insurance — provided their insurance companies agree to cover the medicine.
“I think most plans are going to find it very difficult to deny coverage [for Addyi] if they cover erectile dysfunction drugs” for men, such as Viagra and Cialis, said Walid F. Gellad, an associate professor of medicine at the University of Pittsburgh.
Companies including Highmark Inc. and United Healthcare, the largest health insurers in Pennsylvania and nationwide, respectively, said they’re reviewing the product. The country’s third-largest health insurer, Indianapolis-based Anthem Inc., said last week it will cover Addyi in many cases.
Dr. Gellad expects insurers will hear the same arguments for gender equity that confronted the federal Food and Drug Administration, which approved Addyi on Aug. 18 as the first women’s drug of its kind. It’s scheduled to go on sale by mid-October.
Seventy percent of men with health insurance have coverage for sexual dysfunction drugs, Sprout CEO Cindy Whitehead has said.
“Insurance covers medically necessary medication. They don’t cover what they consider lifestyle,” said Alina Salganicoff, vice president for women’s health policy at the Kaiser Family Foundation in Menlo Park, Calif. She said a woman probably will need a condition diagnosis before her insurer “will even consider” covering Addyi.
Advocates for the prescription-only therapy argue it could help thousands of premenopausal women with hypoactive sexual desire disorder, a condition that diminishes the libido. Raleigh, N.C.-based Sprout estimates as many as 10 percent of American women have the problem.
Addyi could help some of them, though probably fewer than half the women with the condition, said drug researcher Sheryl Kingsberg. She helped study the medication in clinical trials and has spoken on behalf of Sprout before an FDA panel.
“You’re restoring women who lost what had been healthy sexual desires. They had gone to nothing,” said Ms. Kingsberg, a division chief in behavioral medicine at MacDonald Women’s Hospital in Cleveland.
Regulatory approval for Addyi could help clear a path for several similar drugs now in development, one of which could be ready for sale in 18 months to two years, she said.
Downtown-based Highmark will review any alternative therapies in the works as the insurer evaluates Addyi and its effectiveness, a process that can take about 90 days, said Sarah Marche, vice president of pharmacy markets. She said the insurer’s employer clients often cover erectile dysfunction drugs under company-sponsored policies, but they set monthly limits for the treatments.
Addyi differs in part because it’s an everyday pill, unlike Viagra, which is taken only as needed. Although supporters call Addyi safe, critics have cited concerns over potential side effects such as low blood pressure.
“It’s not as straightforward when you’re talking about libido as when you’re talking about Viagra, which is about mechanical function,” said Susan F. Wood, a former assistant commissioner for women’s health at the FDA.
She said private insurers can refuse to cover drugs “because they’re not a particularly good product or particularly effective.”
An Addyi option could be more scarce for patients enrolled in public insurance. The federal Social Security Act bans Pennsylvania Medicaid from covering sexual dysfunction drugs, including Addyi and Viagra, according to the state Department of Human Services.
Such drugs generally are not covered, either, under the basic Medicare Part D benefit, a federal offering to subsidize drug costs for the elderly and disabled, spokesman Aaron Albright said.
Adam Smeltz: asmeltz@post-gazette.com, 412-263-2625 or on Twitter @asmeltz. Bloomberg News and Reuters contributed.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.